Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 19, 2011 11:35 ET | Source: Ventrus Biosciences

Ventrus Biosciences Announces Exercise of Underwriters' Over-Allotment Option and Closing of $51.75 Million Underwritten Registered Offering

NEW YORK, July 19, 2011 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. ("Ventrus") (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, announced...
July 14, 2011 09:18 ET | Source: Ventrus Biosciences

Ventrus Biosciences Announces Pricing of Its Underwritten Registered Offering of Common Stock

NEW YORK, July 14, 2011 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced the...
June 22, 2011 08:00 ET | Source: Ventrus Biosciences

Ventrus Receives SPA Response From FDA and Will Update and File the First Pivotal Trial Protocol to its IND

NEW YORK, June 22, 2011 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS) announced today that it has received a response from the U.S. Food and Drug Administration (FDA) to its last Special...
May 31, 2011 16:00 ET | Source: Ventrus Biosciences

Ventrus Receives Notice of Allowance for U.S. Patent for VEN 307

NEW YORK, May 31, 2011 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. announced today that the claims in its currently pending U.S. Patent Application No. 09/355,928, titled "TOPICAL PHARMACEUTICAL...
May 02, 2011 16:16 ET | Source: Ventrus Biosciences

Ventrus Adds Third Treatment Arm of Shorter Treatment Duration to Its Phase III Study of Iferanserin in Hemorrhoids

NEW YORK, May 2, 2011 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS) announced today that it has added a third treatment arm to its first pivotal Phase III study of Iferanserin (VEN 309),...
March 18, 2011 16:02 ET | Source: Ventrus Biosciences

Ventrus Announces Improved, FDA-Recommended Endpoints Proposed for Phase III Hemorrhoid Study

NEW YORK, March 18, 2011 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS) has filed a revised protocol with the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment...
March 03, 2011 14:24 ET | Source: Ventrus Biosciences

Ventrus Hires inVentiv Clinical Solutions and Almac Group for Its Phase III Pivotal Trial in the Treatment of Hemorrhoids With Iferanserin Ointment

NEW YORK, March 3, 2011 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced that...
February 07, 2011 16:24 ET | Source: Ventrus Biosciences

Ventrus to Present at 2011 BIO CEO & Investor Conference

NEW YORK, Feb. 7, 2011 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, announced today that...
February 01, 2011 14:57 ET | Source: Ventrus Biosciences

Ventrus Completes Clinical Development Staffing

NEW YORK, Feb. 1, 2011 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced the...
January 07, 2011 12:11 ET | Source: Ventrus Biosciences

Underwriters Exercise Over-Allotment Option for Ventrus Biosciences' Initial Public Offering

NEW YORK, Jan. 7, 2011 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. ("Ventrus") (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today...